Patients who took the diet drug Wegovy for a year had a reduced risk of heart disease in an early hint that Novo Nordisk’s best-selling obesity medicine may also have a positive impact on cardiovascular health. People followed in a study saw their 10-year risk of cardiovascular disease decline by 18%, said Andres Acosta, an associate...Read More

Sharon Osbourne opened up about her experience taking an injectable weight loss drug. During Thursday’s episode of “The Talk UK” the 70-year-old television personality and her fellow panelists discussed the explosion in popularity of the injectable medications Wegovy and Ozempic. The conversation was prompted by the news that Wegovy’s U.K. launch has been paused indefinitely due to...Read More

A new category of weight loss medications, repurposed from diabetes treatment, are seriously changing how we think about and approach weight management. In 2021 the medication semaglutide, called a “game changer” in the industry, officially got the FDA’s approval to be prescribed for weight loss. In 2022, it has soared in popularity, becoming more widely...Read More

A new weight-loss shot is being hailed as a “game changer” — with the potential to cut diabetes risk by 50% and “fight obesity as a disease” for the first time, according to a new study. The research, conducted by the University of Alabama, found that weekly jabs of the drug semaglutide in overweight and...Read More

An obesity drug given in weekly jabs more than halves the risk of developing type 2 diabetes, a landmark review suggests. Patients can inject themselves with semaglutide, which works by hijacking the brain to suppress appetite and slash calorie intake. Overweight and obese participants given the regular doses saw their odds of suffering the condition...Read More

GLP-1 is a hormone produced in the small intestine that stimulates insulin sensitivity and inhibits glucagon secretion, thereby lowering blood sugar. Semaglutide is a compounded BioIdentical formulation of GLP-1. How does Semaglutide work? Semaglutide is a compounded formulation of GLP-1, glucagon-like peptide, that was approved in 2017 as a treatment for improving glycemic control in...Read More